Antithrombin III in patients with severe sepsis. A randomized, placeho-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis

Intensive Care Medicine

Volumn 24, Issue 7, 1998, Pages 663-672

  Eisele, B ^a,g   Lamy, M ^b   Thijs, L G ^c   Keinecke, H O ^a   Schuster, H P ^d   Matthias, F R ^e   Fourrier, F ^f   Heinrichs, H ^a   Delvos, U ^a  

^a Centeon Pharma GmbH   (Germany)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d Academic Municipal Hospital   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Antithrombin III; Clinical trial; Meta analysis; Multiorgan failure; Sepsis

Indexed keywords

ANTITHROMBIN III; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTENSIVE CARE; MALE; META ANALYSIS; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

AGED; ANTITHROMBIN III; APACHE; CAUSE OF DEATH; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS;

EID: 0031825290     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050642     Document Type: Article

References (39)

1. Bone RC, Balk RA, Cerra FB (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644-1655
2. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17: 389-393
3. Fisher CJ, Dhainaut JFA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Ibertie TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271: 1836-1843
4. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntytre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell RN (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097-1102
5. Ziegler EJ, Fisher CJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger P, Teng NNH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith CR (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo controlled trial. N Engl J Med 324: 429-436, 486-487
6. Dinarello CA, Gelfand JA, Wolff SM (1993) Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269: 1829-1835
7. Dhainaut F-J A, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet J-P, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira J-P, De Vathaire F, Guinot P (1994) Platelet-activating factor receptor antagonist BN52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22: 1720-1728
8. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 121: 1-5
9. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC (1995) Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome. JAMA 273: 934-941
10. Piguet PF, Grau GE, Vassalli P (1990) Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol 136: 103-110
11. Remick DG, Kunkel RG, Larric JW, Kunkel SL (1987) Acute in vivo effects of human recombinant tumor necrosis factor. Lab Invest 56: 583-590
12. van Deventer SJH, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A (1990) Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 76: 2520-2526
13. Bauer KA, ten Cate H, Barzegar S, Spriggs DR, Sherman ML, Rosenberg RD (1989) Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 74: 165-172
14. van der Poll T, Buller HR, ten Cate H (1990) Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 322: 1622-1627
15. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavei P (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest 101: 816-823
16. Dickneite G, Pâques EP (1993) Reduction of mortality with antithrombin III in septicemic rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 2: 98-102
17. Rao LVM, Nordfang O, Hoang AD, Pendurthi UR (1995) Mechanism of antithrombin III inhibition of factor VIIa/ tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 85: 121-129
18. Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E (1982) Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock 9: 491-497
19. Voss R, Matthias FR, Borkowski G, Reitz D (1990) Activation and inhibition of fibrinolysis in septic patients in an internal intensive care unit. Br J Haematol 75: 99-105
20. Havemann K, Gramse M (1984) Physiology and pathophysiology of neutral proteinases of human granulocytes. In: Hörl WH, Heidland A (eds) Proteases: potential role in health and disease. Plenum, New York, pp 1-20
21. Seitz R, Wolf M, Egbring R, Havemann K (1989) The disturbance of haemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma. Eur J Haematol 43: 22-28
22. Schipper HG, Jenkins CSP, Kahl LH, Ten Cate JW (1978) Antithrombin III transfusion in disseminated intravascular coagulation. Lancet I: 854-856
23. Fourrier F, Chopin C, Huart J, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104: 882-888
24. Schuster HP, Matthias FR (1995) Antithrombin III in severe sepsis. 15th International Symposium of Intensive Care and Emergency Medicine. Brussels, March, 21-24, 1995
25. Knaus WA, Draper EA, Wagner DP, Zimmermann JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818-829
26. Goris RJA, te Boekhorst TPA, Nuytinck JKS, Gimbrère JSF (1985) Multiple-organ-failure. Generalized autodestructive inflammation? Arch Surg 120: 1109-1115
27. Knaus WA, Draper EA, Wagner DP, Zimmermann JE (1985) Prognosis in acute organ system failure (OSF). Ann Surg 202: 685-693
28. Jordan DA, Miller CF, Kubos KL, Rogers MC (1987) Evaluation of sepsis in a critically III surgical population. Crit Care Med 15: 897-904
29. Kleinbaum DG, Kupper LL, Morgenstern H (1982) Epidemiologie research: principles and quantitative methods. Wadsworth, Belmont, CA
30. Galbraith RJ (1988) A note on graphical presentations of estimated odds ratios from several clinical trials. Stat Med 7: 889-894
31. Williams J, Maier RV (1992) The inflammatory response. J Intensive Care Med 7: 53-66
32. Regoeczi E, Brain MC (1969) Organ distribution of fibrin in disseminated intravascular coagulation. Br J Haematol 17: 73-79
33. Robboy SJ, Colman RW, Minna JD (1972) Pathology of disseminated intravascular coagulation (DIC): analysis of twenty-six cases. Hum Pathol 3: 327
34. Taylor FB, Emerson TE, Jordan R, Chang AK, Blick KE (1988) Antithrombin III prevents the lethal effects of Escherichia colt infusion in baboons. Circ Shock 26: 227-235
35. Taylor FB, Chang ACK, Peer GT, Mather T, Blick K, Catlett R, Lockhart MS, Esmon CT (1991) DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 78: 364-368
36. Yamauchi T, Umeda F, Inoguchi T, Nawata H (1989) Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun 163: 1404-1411
37. Horie S, Ishii H, Kazama M (1990) Heparin-like glycosaminoglycan is a receptor for antithrombin III - dependent hut not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 59: 895-904
38. Okajima K, Uchiba M, Murakami K (1995) Antithrombin replacement in DIC and MOF. In: Vincent JL (ed) Yearbook of intensive care and emergency medicine. Springer, Berlin Heidelberg New York, pp 457-464
39. Blauhut B, Kramar H, Vinazzer H, Bergmann H (1985) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39: 81-89